Curis (CRIS) Cash from Investing Activities (2010 - 2025)
Curis' (CRIS) quarterly Cash from Investing Activities came in at $2.5 million in Q4 2025, up 684.11% YoY from $318831.9 in Q4 2024, and up 684.11% on a QoQ basis from -$428000.0 in Q4 2024.
Curis (CRIS) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Curis (CRIS) has 16 years of Cash from Investing Activities data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Cash from Investing Activities rose 684.11% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 76.26% YoY) and the FY2025 annual result came in at $2.5 million, down 91.51% from the prior year.
- Cash from Investing Activities grew to $2.5 million in Q4 2025, from -$428000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $28.3 million in Q2 2022 to a low of -$28.8 million in Q2 2021.
- A 5-year average of $3.2 million and a median of $180000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 11051.55% — and 2024, when it jumped 10076.67%.
- Tracing CRIS's Cash from Investing Activities over 5 years: stood at -$3.5 million in 2021, then jumped by 198.3% to $3.5 million in 2022, then jumped by 319.2% to $14.5 million in 2023, then slumped by 102.95% to -$428000.0 in 2024, then surged by 684.11% to $2.5 million in 2025.
- The last three Cash from Investing Activities figures came in at $2.5 million (Q4 2025), -$428000.0 (Q4 2024), and $18.3 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | -428,000.00 |
| Dec 31, 2024 | -428,000.00 |
| Sep 30, 2024 | 18.32 Mn |
| Sep 30, 2024 | 18.32 Mn |
| Jun 30, 2024 | -7.36 Mn |
| Jun 30, 2024 | -7.36 Mn |
| Mar 31, 2024 | 18.91 Mn |
| Mar 31, 2024 | 18.91 Mn |
| Dec 31, 2023 | 14.52 Mn |
| Dec 31, 2023 | 14.52 Mn |
| Sep 30, 2023 | 180,000.00 |
| Sep 30, 2023 | 180,000.00 |
| Jun 30, 2023 | -3.15 Mn |
| Jun 30, 2023 | -3.15 Mn |
| Mar 31, 2023 | 26.24 Mn |
| Mar 31, 2023 | 26.24 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Dec 31, 2022 | 3.46 Mn |